<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/BDB62FBC-921E-49FF-AD56-909ED429E427"><gtr:id>BDB62FBC-921E-49FF-AD56-909ED429E427</gtr:id><gtr:name>Institute of Tropical Medicine</gtr:name><gtr:address><gtr:line1>Nationalestraat 155</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/C6D0044A-2CD2-4167-B90B-922AF53E361F"><gtr:id>C6D0044A-2CD2-4167-B90B-922AF53E361F</gtr:id><gtr:name>University of Kent</gtr:name><gtr:department>Sch of Biosciences</gtr:department><gtr:address><gtr:line1>The Registry</gtr:line1><gtr:line4>Canterbury</gtr:line4><gtr:line5>Kent</gtr:line5><gtr:postCode>CT2 7NZ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C6D0044A-2CD2-4167-B90B-922AF53E361F"><gtr:id>C6D0044A-2CD2-4167-B90B-922AF53E361F</gtr:id><gtr:name>University of Kent</gtr:name><gtr:address><gtr:line1>The Registry</gtr:line1><gtr:line4>Canterbury</gtr:line4><gtr:line5>Kent</gtr:line5><gtr:postCode>CT2 7NZ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/BDB62FBC-921E-49FF-AD56-909ED429E427"><gtr:id>BDB62FBC-921E-49FF-AD56-909ED429E427</gtr:id><gtr:name>Institute of Tropical Medicine</gtr:name><gtr:address><gtr:line1>Nationalestraat 155</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C9511462-1605-4095-BC4C-F24797BF2FD9"><gtr:id>C9511462-1605-4095-BC4C-F24797BF2FD9</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Mark</gtr:otherNames><gtr:surname>Smales</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FL026279%2F1"><gtr:id>579CC784-D4C1-4A9E-8F38-96686E12F8D4</gtr:id><gtr:title>FLIP Expression of recombinant target antigens for neglected tropical diseases in surrogate organisms</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/L026279/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Not required.</gtr:technicalSummary><gtr:potentialImpactText>Not required.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-09-26</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2014-01-27</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>116607</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Tropical Medicine Antwerp</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Tropical Institute Collaboration</gtr:description><gtr:id>7A4B4C85-3E95-49C7-BF39-D3ED253ACBE8</gtr:id><gtr:impact>Development of new diagnostic for sleeping sickness that is now in field trial in Africa.</gtr:impact><gtr:partnerContribution>Providing serum and samples to test and validate antigens and diagnostics.</gtr:partnerContribution><gtr:piContribution>Development of recombinant antigens for rapid diagnostic test for sleeping sickness.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Barrie Rooney spoke on BBC Radio Kent about working in Africa with contagious diseases</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C019CAC5-1347-4147-A0B3-5CAA80EFE8A2</gtr:id><gtr:impact>Discussion afterwards.

Asked about tropical diseases.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/p027d7jt</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Turkey Public Biotechnology Talk</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F242D4EA-26B2-4696-834E-63B610243957</gtr:id><gtr:impact>Presentation to public audience in Turkey on behalf of the British Council around biotechnology and its application. Event was filmed and followed by a question and answer session, answering questions sent in before the talk by social media and then from the audience. The event was filmed and shown on national TV in Turkey. Large range of topics discussed around the application of biotechnology to every day life and issues with long discussion/debate.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.britishcouncil.org.tr/en/programmes/education/science-innovation-talks/biotechnology</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit/outreach for several days at Simon Langton Boys Grammar - MBP2 project showing students how to clone, express and purify recombinant proteins in the laboratory and discuss science behind this.</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>985A6AD4-527F-4407-B08E-7499C9D5FB56</gtr:id><gtr:impact>Helping with research activity in school - cloning and expression of recombinant proteins</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open Days At University</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>03958126-4ED4-4A0B-A853-1A230C09FE96</gtr:id><gtr:impact>This activity is take take parents and secondary students around my research laboratories to explain the research undertaken and to demonstrate some of the research that we do in the laboratory.

Parents and students asked about engineering of cell lines and therapeutic recombinant protein drugs and how these are made, cost implications and on-going research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>7 open days at University</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3BE9AC96-294B-49E0-A785-0A0D810B06A5</gtr:id><gtr:impact>Describing the research we undertake in the laboratory, covering all aspects of the research and the impact this has/can have. Particular questions around genetic modification of cells to produce recombinant proteins in all sessions and discussions around both the ethical aspects of this and the potential applications of such technology.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Outreach Presentation on Diagnostics for Neglected Tropical Diseases</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CB2C90EA-F8FE-4FA3-BFF6-D7D3DC05FB12</gtr:id><gtr:impact>Rotary Club Presentation on Diagnostics</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The project has developed new antigens for the use in diagnostics for human African Trypanosomiasis (HAT, sleeping sickness). These were evaluated in collaboration with the tropical medicine institute in Belgium who have provided access to appropriate samples. This showed that these antigens gave superior diagnostic capability over current antigens. These findings are now being taken forward and developed further to investigate the development of new diagnostics for use in the field.</gtr:description><gtr:firstYearOfImpact>2015</gtr:firstYearOfImpact><gtr:id>6603408D-87EF-4FDA-B8F8-B1735DB6FEA8</gtr:id><gtr:impactTypes><gtr:impactType>Cultural,Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Despite the massive expansion of technologies and biotherapeutic drugs over he last 20+ years, little of this enormous effort, either at the drug target or drug product level, or at the level of developing novel expression technologies for difficult to express proteins, has focussed upon application of such approaches and technologies to developing new drugs, detection and diagnostic tools, or expression systems for biotherapeutics in the area of neglected tropical diseases. One such example is the in the area of human African Trypanosomiasis (HAT, sleeping sickness). This disease threatens millions of people in the sub-Saharan area of Africa. The development of new, more reliable and economic diagnostic biomarkers and assays is essential, particularly for distinguishing between early and late stages of the disease to inform the drug regimen used if this disease is to be reduced further in the sub-Saharan. As such, some recent developments in this area have focussed upon identification and validation of new diagnostic markers of HAT to complement or improve upon the current Card Agglutination Test for Trypanosomiasis (CATT), whilst others continue to investigate the possibility of developing a vaccination to this disease. Hence, for both the development of new diagnostics and for potential new vaccines, the availability of appropriate expression systems for the generation of recombinant protein molecules is required. 

He we have used existing expression systems and applied them to new areas of need/challenges with a view to create a new platform technology which could be used for tropical zoonotic diseases.

So far through the project we have
1. Established a collaboration between the University of Kent and the charity Medecins Sans Frontieres (MSF).
2. Established the LEXSY expression system in the laboratory at Kent for the generation of novel antigens to use in new diagnostics for HAT. 
3. Generated appropriate constructs for HAT antigens, and constructs for a model IgA for expression in the LEXSY expression system (Leishmania).
4. Undertake preliminary expression of the model antigen proteins by transforming Leishmania cells by electroporation and purifying the expressed proteins by His tag chromatography (for the tagged HAT antigens).
5. Begun to characterise the glycosylation of model proteins produced in LEXSY cells.
6. Begun to assess the antigenic properties of these targets in collaboration with the Tropical Institute of Medicine in Belgium.
8. Development of an ELSIA based diagnostic for HAT.

The overall objective is for the development of new HAT diagnostics in the field. We are now taking the findings further forward using a follow-on-fund grant to commercialise the technology.</gtr:description><gtr:exploitationPathways>These findings will be able to be developed by others in the field looking to develop new rapid, pint of care and low cost diagnostics for tropical diseases, specifically for HAT.</gtr:exploitationPathways><gtr:id>FBC0DC45-527D-478E-8818-150F6D79AC9B</gtr:id><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/797C5315-CE5F-4529-B6D2-1349D1103080"><gtr:id>797C5315-CE5F-4529-B6D2-1349D1103080</gtr:id><gtr:title>Expression of Trypanosoma brucei gambiense Antigens in Leishmania tarentolae. Potential for Use in Rapid Serodiagnostic Tests (RDTs).</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/57c02fb0d995347c2744e68192b618c3"><gtr:id>57c02fb0d995347c2744e68192b618c3</gtr:id><gtr:otherNames>Rooney B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/L026279/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>17F21DBC-4946-4262-AD07-9914F6EA12F7</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Bioengineering</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>A442BF36-F335-483E-9282-F3BB48AC2C47</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Cell biology</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>99E0B904-CAB5-4511-AFB3-AA6D2B171F97</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Process engineering</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>18D298A9-FFE3-432F-B077-E3B703272E29</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biochemical engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>649031FD-C21E-42D9-AC12-41ACA59CC11C</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biochemistry &amp; physiology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>9C387DA5-CD5F-43E4-AA74-82CBF4DB6617</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Bioprocess Engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>D16FDB98-8CBA-4298-8ACD-955DF734E7F5</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Cells</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>9031EBB8-791D-4466-9E80-80F98BCB26E1</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Protein expression</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>